[Malignant melanoma]

Same author

Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285].

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS).

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same journal

[Tennis Elbow Among Players].

Harefuah·2026

Same journal

[Internal Medicine - My Mission].

Harefuah·2026

Same journal

[Treatment of Morbid Obesity in Israel: GLP-1 Agonists Versus Bariatric Surgery - Clinical and Economic Aspects].

Harefuah·2026

Same journal

[Baby steps: Post-operative Treatment Recommendations for Pediatric Tracheostomy in Israel].

Harefuah·2026

Same journal

[Mastoiditis Caused by Fusobacterium Necrophorum: an Unusual Pathogen in a Well-Known Disease].

Harefuah·2026

Same journal

[Cochlear Implantation in Single-Sided Deafness - Six Years of Follow-Up from Diagnosis and Consistent Use, Through Dedicated and Creative Auditory Learning, to the Development of Bilateral Central Processing Abilities].

Harefuah·2026

Related Experiment Videos

[Malignant melanoma]

Related Concept Videos

Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285].

Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS).

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

[Tennis Elbow Among Players].

[Internal Medicine - My Mission].

[Treatment of Morbid Obesity in Israel: GLP-1 Agonists Versus Bariatric Surgery - Clinical and Economic Aspects].

[Baby steps: Post-operative Treatment Recommendations for Pediatric Tracheostomy in Israel].

[Mastoiditis Caused by Fusobacterium Necrophorum: an Unusual Pathogen in a Well-Known Disease].

[Cochlear Implantation in Single-Sided Deafness - Six Years of Follow-Up from Diagnosis and Consistent Use, Through Dedicated and Creative Auditory Learning, to the Development of Bilateral Central Processing Abilities].

Related Experiment Videos

[Malignant melanoma]

Related Concept Videos

Related Articles

Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285].

Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS).

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

[Tennis Elbow Among Players].

[Internal Medicine - My Mission].

[Treatment of Morbid Obesity in Israel: GLP-1 Agonists Versus Bariatric Surgery - Clinical and Economic Aspects].

[Baby steps: Post-operative Treatment Recommendations for Pediatric Tracheostomy in Israel].

[Mastoiditis Caused by Fusobacterium Necrophorum: an Unusual Pathogen in a Well-Known Disease].

[Cochlear Implantation in Single-Sided Deafness - Six Years of Follow-Up from Diagnosis and Consistent Use, Through Dedicated and Creative Auditory Learning, to the Development of Bilateral Central Processing Abilities].